Dear Sir,

We appreciate the keen interest taken by Drs. Mahajan and Gaur for sending a correspondence in response to our article titled "Comorbidities in COVID-19: outcomes in hypertensive cohort and controversies with renin angiotensin system blockers" \[[@bib1]\].

Although the authors are in agreement with the findings in general, however they have raised two questions in the correspondence. We agree that angiotensin-converting enzyme inhibitors do not increase angiotensin II, while angiotensin-receptor blockers have the potential to increase it. However, the hypothesis that the interaction of angiotensin converting enzyme-2 (ACE-2) with angiotensin II could lead to a conformational change in the receptor binding domain of ACE2 is not unfounded and has been put forth in the study on the X-Ray structure of ACE-2 \[[@bib2]\]. With regards to other query about the purported protection of lung injury by the renin angiotensin system blockers (RASBs), we humbly inform that it has already been dealt with a great detail, which authors seems to have overlooked. Similarly, the figures in our article has much more detailed information on the interaction of renin angiotensin system blockers (RASBs), ACE-2 and coronavirus infectious disease 2019 (COVID-19).

We would like to reiterate again, that the benefit or harm with RASBs in COVID-19 is still a subject of debate and data at this point of time suggest a clinical equipoise. Some studies have shown a purported harm \[[@bib3],[@bib4]\], while others have shown benefit \[[@bib5]\]; the reason why we discussed both these issues in detail. However, we do not recommend to stop the RASB in patient with COVID-19.
